Palatin Technologies Inc - Company & Market Research Reports

Palatin Technologies is a biopharmaceutical company that develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company’s leading product is Bremelanotide, which is used to treat hypoactive sexual desire disorder (HSDD). It has completed pivotal Phase 3 clinical trials. Palatin also has development programs or drug candidates for inflammatory disease indications, heart failure and fibrosis. It was founded in 1986 and is based in Cranbury, New Jersey.

Global Lifestyle Drugs Market 2017-2021 - Product Thumbnail Image

Global Lifestyle Drugs Market 2017-2021

  • Report
  • 91 Pages
From
Ulcerative Colitis - Pipeline Review, H1 2018 - Product Thumbnail Image

Ulcerative Colitis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 482 Pages
From
Obesity Drugs and Therapies: Technologies and Global Markets - Product Thumbnail Image

Obesity Drugs and Therapies: Technologies and Global Markets

  • Report
From
Uveitis - Pipeline Review, H2 2018 - Product Thumbnail Image

Uveitis - Pipeline Review, H2 2018

  • Drug Pipelines
  • 207 Pages
From
Uveitis - Pipeline Review, H1 2018 - Product Thumbnail Image

Uveitis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 195 Pages
From
Inflammatory Bowel Disease - Pipeline Review, H2 2015 - Product Thumbnail Image

Inflammatory Bowel Disease - Pipeline Review, H2 2015

  • Drug Pipelines
  • 1025 Pages
From
Peptide Therapeutics in Metabolic Disorders, 2016 - 2025 - Product Thumbnail Image

Peptide Therapeutics in Metabolic Disorders, 2016 - 2025

  • Report
  • 436 Pages
From
Global Sexual Dysfunction Drugs Market 2017-2021 - Product Thumbnail Image

Global Sexual Dysfunction Drugs Market 2017-2021

  • Report
  • 91 Pages
From
Obesity - Pipeline Review, H1 2018 - Product Thumbnail Image

Obesity - Pipeline Review, H1 2018

  • Drug Pipelines
  • 526 Pages
From
Obesity - Pipeline Review, H2 2017 - Product Thumbnail Image

Obesity - Pipeline Review, H2 2017

  • Drug Pipelines
  • 518 Pages
From
Melanocortin 4 Receptor (MC4R) Agonist -Pipeline Insight, 2018 - Product Thumbnail Image

Melanocortin 4 Receptor (MC4R) Agonist -Pipeline Insight, 2018

  • Drug Pipelines
  • 60 Pages
From
Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018 - Product Thumbnail Image

Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018

  • Report
  • 344 Pages
From
Antibody Discovery: Services and Platforms, 2017-2027 - Product Thumbnail Image

Antibody Discovery: Services and Platforms, 2017-2027

  • Report
  • 306 Pages
From
Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2018 - Product Thumbnail Image

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2018

  • Drug Pipelines
  • 60 Pages
From
Female Sexual Dysfunction - Pipeline Review, H1 2018 - Product Thumbnail Image

Female Sexual Dysfunction - Pipeline Review, H1 2018

  • Drug Pipelines
  • 67 Pages
From
Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2018 - Product Thumbnail Image

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2018

  • Drug Pipelines
  • 49 Pages
From
Antibody Humanization and Affinity Maturation: Services and Platforms, 2017-2030 - Product Thumbnail Image

Antibody Humanization and Affinity Maturation: Services and Platforms, 2017-2030

  • Report
  • 224 Pages
From
Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2018 - Product Thumbnail Image

Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2018

  • Drug Pipelines
  • 441 Pages
From
Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2018 - Product Thumbnail Image

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2018

  • Drug Pipelines
  • 420 Pages
From
Myocardial Fibrosis - Pipeline Review, H2 2017 - Product Thumbnail Image

Myocardial Fibrosis - Pipeline Review, H2 2017

  • Drug Pipelines
  • 85 Pages
From
Loading Indicator
adroll